Leukocyte disorder

This early-phase trial tests whether a bone marrow transplant from a partially matched relative can safely cure chronic granulomatous disease (CGD), a condition that causes severe infections and inflammation. Four people aged 4 to 65 with CGD and no perfect donor will receive che…

This trial tests a personalized therapy where a patient's own T cells are collected, genetically modified to recognize and attack CD19-positive leukemia cells, and then infused back into the patient. It is designed for children and young adults with relapsed or refractory CD19+ a…

This trial tests a new, lower-intensity combination of chemotherapy and radiation before a donor stem cell transplant for people with high-risk blood cancers or aplastic anemia. The goal is to see if this approach is safe enough to allow the donor cells to take hold and cure the …

This early-phase trial is testing a new gene therapy called ESO-T01 for people with relapsed or refractory multiple myeloma, a blood cancer that has stopped responding to standard treatments. ESO-T01 is given as an injection and works by instructing the body's own cells to become…

This early-stage trial is testing whether a second infusion of a patient's own genetically modified immune cells (CAR T-cells) can safely treat B-cell lymphoma that has returned after an initial successful response. The study enrolls people with diffuse large B-cell or follicular…

This study tests a new type of immune cell therapy for people with CD19-positive leukemia or lymphoma who have had a stem cell transplant. The cells are specially designed to both recognize and kill cancer cells (through a CD19-targeting antibody) and fight three common viruses (…

This phase II trial tests a vaccine designed to protect stem cell transplant recipients from cytomegalovirus (CMV), a common virus that can cause serious illness in people with weakened immune systems. The vaccine uses a modified, harmless virus to deliver three CMV proteins, tra…

This early-phase trial tests whether a vaccine made from a protein called survivin can safely boost the immune system to fight multiple myeloma. The study involves 18 patients who have already responded to initial treatment and are taking lenalidomide as maintenance therapy. The …

This study looks at how well a pneumonia vaccine (PCV20) works in people who have recovered from B-cell lymphoma and were treated with anti-CD20 therapy. Researchers want to see if a single dose or a boosted dose is safer and more effective at preventing pneumococcal infections. …

This study tests a new COVID-19 vaccine (GEO-CM04S1) in 63 adults with blood cancers like leukemia or lymphoma who have had a stem cell transplant or cell therapy. The goal is to see if this vaccine triggers a stronger immune response than standard mRNA vaccines, potentially offe…

This study tests whether a lower dose of the drug cyclophosphamide, given after a stem cell transplant from a partially matched donor, can reduce serious infections in the first 100 days while still preventing graft-versus-host disease (a common complication where donor cells att…

This phase 2 trial tests a combination of three drugs—daratumumab, carfilzomib, and dexamethasone (DKd)—in people with high-risk smoldering multiple myeloma, a pre-cancer condition. The goal is to see if this treatment can prevent or delay the disease from turning into active mul…

This early-stage trial is testing the safety of adding venetoclax to standard multiple myeloma treatments for people whose cancer cells have a specific genetic change called t(11;14). The study will enroll 100 participants and try different drug combinations to find the best dose…

This study tests an experimental drug called CHO-H01, alone or with lenalidomide, in people with non-Hodgkin lymphoma that has returned or not responded to prior treatments. The trial has two parts: first, finding a safe dose of CHO-H01 alone; second, testing the combination in l…

This study tests a high-dose stem cell transplant for people with chronic granulomatous disease (CGD), a condition that weakens the immune system. Participants receive donor stem cells along with drugs to prevent rejection and graft-versus-host disease. The goal is to improve tra…

This phase 3 trial tests whether adding isatuximab to iberdomide maintenance therapy after a stem cell transplant can reduce cancer cells in the bone marrow more than iberdomide alone. About 411 adults with newly diagnosed multiple myeloma will participate. The goal is to see if …

This early-stage trial is testing whether combining two existing immunotherapy drugs (mosunetuzumab or glofitamab) with newer oral drugs (iberdomide and/or golcadomide) can safely treat B-cell non-Hodgkin lymphoma that has come back or not responded to previous treatments. About …

This study tests a modified schedule of standard chemotherapy (R-CHOP) for people aged 75 and older with diffuse large B-cell lymphoma, a type of blood cancer. The goal is to see if splitting the doses makes treatment easier to tolerate while still being effective. Twenty-seven p…

This early-phase trial is testing an experimental antibody called cevostamab, either alone or combined with other drugs (pomalidomide, daratumumab, and dexamethasone), in 126 people with multiple myeloma that has returned or stopped responding to treatment. The main goals are to …

This study tests two oral drugs, mirdametinib and sirolimus, in people with relapsed or refractory multiple myeloma that has specific RAS gene mutations. The trial has two phases: first to find a safe dose, then to see how well the combo works. Up to 54 adults will take the drugs…

This early-phase trial tests a combination of the targeted drug ibrutinib with several chemotherapy drugs (TEDDI-R) in people with primary CNS lymphoma, a rare and aggressive brain cancer. The study aims to find the safest dose of ibrutinib when used in this cocktail and to see h…

This phase 2 trial is testing a new drug called zilovertamab vedotin (MK-2140), alone or with another drug nemtabrutinib, in about 189 people with several types of B-cell blood cancers that have come back or not responded to prior treatments. The main goals are to see if the trea…

This study tests a gene therapy for people with X-linked chronic granulomatous disease (X-CGD), a genetic condition that weakens the immune system and leads to severe infections. Researchers take the patient's own stem cells, add a working copy of the faulty gene, and return the …

This early-stage trial is testing whether a combination of tumor-specific immune cells (TAA-T) and the drug nivolumab can safely help people with lymphoma that has returned or not responded to treatment. Participants receive two infusions of TAA-T cells along with nivolumab, whic…

This early-stage study tests a new drug called etentamig combined with standard treatments for people with multiple myeloma that has come back or stopped responding to therapy. About 320 adults will take part to find the safest dose and check for side effects. The goal is to cont…

This early-stage trial is testing a new drug called ABBV-291 in adults with Non-Hodgkin's lymphoma that has come back or stopped responding to treatment. The study will first find the safest dose, then check if the drug can shrink tumors. About 165 participants will take part wor…

This study tests whether giving the drug anakinra early can prevent severe cytokine release syndrome (CRS) in children and young adults with B-cell acute lymphoblastic leukemia (B-ALL) who are receiving CAR-T cell therapy. Participants receive anakinra at the first sign of fever,…

This early-stage trial tests two new drug combinations for people with multiple myeloma that has returned or stopped responding to treatment. One group gets elranatamab (an immune-boosting shot) plus carfilzomib and dexamethasone; the other gets elranatamab plus maplirpacept. The…

This study tests a combination of four drugs—daratumumab, carfilzomib, lenalidomide, and dexamethasone—in 39 adults newly diagnosed with multiple myeloma, a blood cancer. The goal is to see how many patients achieve a complete or stringent complete response after initial treatmen…

This trial tests whether a type of personalized cell therapy called CAR T-cell therapy (axi-cel) can safely treat lymphoma that has returned or not responded to treatment in the central nervous system (brain and spinal cord). The study includes people with primary CNS lymphoma or…

This early-phase trial is testing a two-step approach for people with newly diagnosed, high-risk mantle cell lymphoma. First, patients receive a combination of acalabrutinib (a targeted drug) and rituximab (an antibody). Then, they get a one-time infusion of their own genetically…

This study looks at whether adding the drug rituximab to standard radiation therapy helps people with early-stage follicular lymphoma stay cancer-free longer. About 81 patients with stage I or II low-grade lymphoma are being randomly assigned to get radiation alone or radiation p…

This study tests a drug called blinatumomab, given as a shot under the skin, combined with low-intensity chemotherapy for people aged 60 and older (or younger adults who are not healthy enough for strong chemo) with B-cell acute lymphoblastic leukemia. The goal is to see if this …

This study tests a drug called larotrectinib in 35 adults with advanced cancers (including lymphoma and solid tumors) that have a specific NTRK gene fusion. The drug blocks a faulty protein that tells cancer cells to grow, aiming to shrink tumors or stop them from spreading. Part…

This trial is testing whether a combination of three drugs—ixazomib, pomalidomide, and dexamethasone—can help people with multiple myeloma that has relapsed or become resistant after prior treatments like daratumumab, lenalidomide, and bortezomib. The study will measure how long …

This phase II trial is testing whether adding the drug asciminib to standard treatment can improve outcomes for people newly diagnosed with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL). The study will enroll 55 participants and involves several phases o…

This trial tests whether adjusting the dose of prednisone, a steroid in the R-CHOP chemotherapy regimen, can prevent high blood sugar (hyperglycemia) in adults with B-cell non-Hodgkin lymphoma. Participants are randomly assigned to either the standard prednisone dose or a tailore…

This trial is testing whether adding the experimental drug tazemetostat to the standard R-CHOP chemotherapy regimen can improve outcomes for people newly diagnosed with diffuse large B-cell lymphoma (DLBCL) or high-risk follicular lymphoma. The study has two parts: first, to find…

This phase II trial tests a combination of two targeted drugs, venetoclax and ibrutinib, in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma. The study includes patients whose cancer has come back or is hard to treat, as well as some untreated patients…

This early-phase study tests a new drug (XmAb24306) combined with another drug (cevostamab) in people with multiple myeloma that has come back or stopped responding to at least three prior treatments. The main goal is to check safety and find the right dose. About 90 participants…

This study tests a new treatment called SJCAR19 for children and young adults up to age 21 whose B-cell acute lymphoblastic leukemia (ALL) has come back or not responded to standard therapy. The treatment uses the patient's own immune cells, which are collected, modified in a lab…

This early-phase trial is testing a type of immunotherapy called CD19CAR T-cells in people aged 16 and older with relapsed or refractory primary CNS lymphoma, a rare cancer of the brain or spinal cord. The treatment involves collecting a patient's own immune cells, engineering th…

This early-phase trial is testing whether adding the targeted drug ibrutinib to standard chemotherapy can safely treat HIV-positive patients with a type of lymphoma. The study involves 46 participants and aims to find the best dose and check for side effects. If it works, this co…

This early-stage trial is testing a new drug called SG301 in about 61 people with blood cancers like multiple myeloma that have returned or not responded to standard treatments. The main goal is to check the drug's safety and find the best dose to use in future studies. Researche…

This phase 2 trial is testing several new drug combinations for people with aggressive B-cell lymphoma that has come back or not responded to standard therapy. About 129 participants will receive one of several experimental combinations, including drugs like ibrutinib and selinex…

This phase II trial is testing two oral drugs, venetoclax and acalabrutinib, in 32 people with mantle cell lymphoma that has returned or not responded to prior treatment. The goal is to see if the combination can shrink tumors and control the disease. Both drugs work by blocking …

This study is for people with high-risk chronic lymphocytic leukemia (CLL) who have been on ibrutinib or acalabrutinib for at least a year but still have detectable disease. Researchers want to see if adding venetoclax for 12 cycles can clear remaining leukemia cells from the bon…

This study is for people with follicular lymphoma, a type of blood cancer, that has come back or no longer responds to treatment. It tests whether adding the drug tazemetostat to standard therapy (lenalidomide plus rituximab) helps keep the cancer from growing longer than the sta…

This phase 2 trial is testing whether adding the targeted drug belantamab mafodotin before and after a stem cell transplant can help people with multiple myeloma achieve deeper remission. About 41 participants will receive the drug alongside standard treatments. The main goal is …

This study tests the drug zanubrutinib (Brukinsa) in 18 Chinese adults who have Waldenström macroglobulinemia but have not yet received any treatment. The goal is to see how well the drug controls the disease and to check for side effects. Participants take zanubrutinib by mouth,…

This phase 2 trial tests a combination of three drugs—atezolizumab, obinutuzumab, and venetoclax—in 50 adults with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma, or Richter syndrome that has returned or not responded to prior treatment. The goal is to see if the …

This Phase 3 trial is testing an experimental oral drug called BGB-16673 against standard treatments (bendamustine plus rituximab or high-dose methylprednisolone plus rituximab) in 150 people with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymp…

This phase II trial tests inotuzumab ozogamicin, a drug that targets and kills leukemia cells carrying a specific marker (CD22). It enrolls 40 adults with B-cell acute lymphoblastic leukemia who are in remission but still have minimal residual disease (MRD) — tiny amounts of canc…

This study tests a combination of two drugs, acalabrutinib and rituximab, in people aged 65 and older with newly diagnosed mantle cell lymphoma who haven't had treatment yet. Acalabrutinib blocks enzymes that help cancer grow, while rituximab targets and kills cancer cells. The g…

This study tests a combination of two drugs—venetoclax and vincristine—in people with T-cell or B-cell acute lymphoblastic leukemia that has returned or not responded to prior treatment. The goal is to find the safest dose and see if the combo can lead to remission. About 40 adul…

This early-phase trial is testing a new type of CAR T cell therapy called TriPRIL for people with multiple myeloma that has returned or stopped responding to standard treatments. The therapy involves collecting a patient's own immune cells, modifying them to better attack cancer,…

This Phase 3 trial compares a new two-drug combination (sonrotoclax plus zanubrutinib) against a standard therapy (venetoclax plus obinutuzumab) in 652 adults with previously untreated chronic lymphocytic leukemia (CLL). The goal is to see which approach better delays disease pro…

This early-phase study tests a new drug (glofitamab) combined with two chemotherapy drugs (gemcitabine and oxaliplatin) in about 50 U.S. adults whose diffuse large B-cell lymphoma has returned or stopped responding to prior treatment. The main goals are to check safety and see ho…

This trial is testing whether adding the targeted drug acalabrutinib to the standard CHOP-R chemotherapy regimen can improve outcomes for people newly diagnosed with Richter's syndrome, an aggressive lymphoma that can develop from chronic lymphocytic leukemia (CLL). Richter's syn…

This study tests a specific timing of chemotherapy drugs (busulfan and fludarabine) before a donor stem cell transplant, followed by cyclophosphamide after the transplant, to treat high-risk blood cancers like leukemia and lymphoma. The goal is to reduce the chance of the transpl…

This phase 3 trial is testing whether a combination of zanubrutinib (a targeted cancer pill) plus an anti-CD20 antibody works better than the current standard of lenalidomide plus rituximab for people with relapsed or refractory follicular or marginal zone lymphoma. About 780 par…

This early study tests a new drug called ABBV-101 in people with several types of non-Hodgkin lymphoma that have come back or not responded to other treatments. The drug is a pill that targets a protein (BTK) involved in cancer growth. The main goals are to find a safe dose and s…

This study tests the drug pembrolizumab in people with certain aggressive lymphomas or rare histiocyte/dendritic cell cancers that have come back or not responded to treatment. The goal is to see if the drug can shrink tumors. The study is currently suspended and enrolled 18 part…

This study tests a drug called cevostamab in 90 people with multiple myeloma that has returned or not responded to prior treatments, including BCMA-targeted therapies. Participants receive cevostamab by IV every 3 weeks. The goal is to see if the drug can shrink tumors and how sa…

This phase 2 trial tests whether combining belantamab mafodotin (a targeted antibody-drug conjugate) with lenalidomide can eliminate minimal residual disease in multiple myeloma patients who still have detectable cancer after a stem cell transplant. The study enrolls 4 adults who…

This study tests whether combining two drugs, epcoritamab and lenalidomide, can shrink or eliminate tumors in people with untreated follicular lymphoma, a slow-growing blood cancer that is not currently curable. About 29 adults with stage 1-3a disease who need treatment will rece…

This phase 3 study tests whether a combination of two targeted drugs (mosunetuzumab and polatuzumab vedotin) works better than a standard chemotherapy regimen for people with aggressive B-cell non-Hodgkin lymphoma that has returned or not responded to prior therapy. About 208 adu…

This early-stage trial tests whether specially trained immune cells can safely target and attack multiple myeloma, as well as its early forms MGUS and smoldering myeloma. Up to 36 participants will receive two infusions of their own T cells that have been engineered to recognize …

This early-stage study tests a new cell therapy for adults with a hard-to-treat type of leukemia (ALL). Doctors take a patient's own white blood cells, add a special gene to help them find and kill cancer cells, and give them back after chemotherapy. The main goals are to check s…

This phase 2 trial tests whether daratumumab, an antibody that targets cancer cells, can improve outcomes for people with multiple myeloma after they receive a stem cell transplant. The study involves 31 participants and is currently active but not recruiting. The main goal is to…

This phase 2 trial tests whether the drug iberdomide, taken after CAR-T therapy, can keep multiple myeloma under control longer than just monitoring. About 78 participants will be randomly assigned to receive iberdomide or standard monitoring. The study is currently suspended.

This study tests an experimental antibody called epcoritamab, which helps the immune system target and kill cancer cells. It is being tested alone or with other drugs in about 194 people with relapsed/refractory chronic lymphocytic leukemia (CLL) or Richter's syndrome. The goal i…

This trial tests an antibody called epcoritamab in 666 people with B-cell lymphoma that has come back or not responded to treatment. The drug is designed to help the immune system attack cancer cells. The study looks at safety, the right dose, and how well the drug works.

This study tested whether a combination of ibrutinib (a targeted drug) and rituximab works better than standard chemotherapy (FCR) for younger patients with untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma. About 529 people took part. The main goal was t…

This study tests a drug called ACP-196 (acalabrutinib) in 124 adults with mantle cell lymphoma that has returned or not responded to prior therapy. The main goal is to see how many patients have their tumors shrink or disappear. This is an open-label, phase 2 trial, meaning every…

This study tests whether adding the investigational drug epcoritamab to standard therapy (rituximab and lenalidomide) works better than standard chemoimmunotherapy for people with untreated follicular lymphoma, a slow-growing blood cancer. About 1,095 adults will be randomly assi…

This study tests a drug called epcoritamab, alone or with other treatments, in people with B-cell non-Hodgkin lymphoma, a type of blood cancer. The goal is to find the best dose and see how well it works. About 543 participants will receive the drug under the skin or through an I…

This study tests whether adding the drug venetoclax to standard chemotherapy can keep high-grade B-cell lymphomas from returning or getting worse. The trial includes 363 people with aggressive lymphoma subtypes. Venetoclax targets a protein that helps cancer cells survive, while …

This phase 3 trial is testing whether adding venetoclax to a standard two-drug regimen (ibrutinib and obinutuzumab) helps younger patients with chronic lymphocytic leukemia (CLL) live longer without their cancer getting worse. The study involves 720 participants who have not yet …

This phase 3 trial compares the usual two-drug therapy (ibrutinib plus obinutuzumab) against a three-drug combo that adds venetoclax in older adults (65+) with untreated chronic lymphocytic leukemia. The goal is to see if the extra drug keeps the cancer away longer and whether pa…

This study follows 192 people with chronic lymphocytic leukemia (CLL) in Spain who started taking acalabrutinib for the first time. Researchers want to see how many patients stay on the drug for at least 24 months and how it works in different groups, like those new to treatment …

This study compares the drug lenalidomide to simply watching and waiting in people with high-risk smoldering multiple myeloma, a condition that may turn into active cancer. The goal is to see if lenalidomide can delay progression and improve outcomes. About 226 participants were …

This study tested a combination of the immunotherapy drug blinatumomab with either standard chemotherapy or dasatinib and prednisone in adults aged 65 and older with acute lymphoblastic leukemia (ALL). The goal was to see if the combination could improve survival and control the …

This Phase III trial is testing whether adding the immunotherapy drug blinatumomab to standard chemotherapy helps adults with a newly diagnosed type of acute lymphoblastic leukemia (ALL) live longer and stay cancer-free longer. About 488 participants are randomly assigned to rece…

This trial tests a drug called epcoritamab in about 78 Japanese adults with B-cell lymphoma that has returned or not improved after standard treatment. The study has two parts: first, finding a safe dose, and then checking how well the drug works alone or with other chemotherapy.…

This phase 2 trial tests the drug selpercatinib in children and young adults (ages 1 to 21) with advanced cancers that have a specific genetic change called a RET alteration. The goal is to see if the drug can shrink tumors or stop them from growing. Only one participant has been…

This study offers continued treatment with isatuximab (a targeted antibody) to adults with multiple myeloma who were already benefiting from it in earlier trials. About 70 participants will receive the drug, possibly combined with other medications, to monitor long-term safety. T…

This study tests a cancer pill called venetoclax in 14 Japanese adults with a rare blood cancer (Waldenström macroglobulinemia) that has come back or not responded to treatment. Participants take the drug by mouth daily, with doses slowly increased. The main goal is to see how ma…

This phase 2 trial tests whether a combination of daratumumab, lenalidomide, and dexamethasone, followed by a stronger regimen if needed, can make multiple myeloma undetectable at a deep level (MRD-negative) in newly diagnosed patients. The treatment plan adapts based on each per…

This phase 1 trial tests whether a special imaging tracer can track CAR-T cells in people with extramedullary myeloma, a type of myeloma that forms tumors outside the bone marrow. Participants receive cilta-cel, a CAR-T therapy targeting the BCMA protein on myeloma cells, along w…

This phase 2 trial tests whether adding isatuximab to standard stem cell transplant procedures can help the immune system better fight multiple myeloma and certain lymphomas. Participants are randomly assigned to receive either standard transplant care alone or isatuximab plus st…

This phase 3 trial is testing whether adding the targeted drug ibrutinib to standard rituximab therapy can improve outcomes for people with untreated marginal zone lymphoma, a slow-growing blood cancer. Participants are randomly assigned to receive either ibrutinib plus rituximab…

This trial tests whether adding acalabrutinib—a targeted drug that blocks a key enzyme in cancer cells—to a standard chemotherapy cocktail (modified VR-CAP) can improve outcomes for people with mantle cell lymphoma who are eligible for a stem cell transplant. The study enrolls ad…

This phase 2 trial is testing whether adding the antibody rituximab to either pentostatin or bendamustine can improve outcomes for people with hairy cell leukemia that has relapsed or not responded to standard treatments. Participants are randomly assigned to one of the two drug …

This study tests a new way to treat children and young adults with high-risk blood cancers like leukemia and lymphoma. Doctors take blood cells from a family donor, remove certain T cells that can cause a harmful immune reaction, and then transplant the modified cells. The goal i…

This early-phase trial tests a new type of immune cell therapy called WU-CART-007 for people with certain blood cancers, including acute myeloid leukemia and T-cell lymphoma, that have come back or not responded to treatment. The therapy uses donor cells that are genetically modi…

This early study is testing whether bone marrow from deceased donors can be safely used for transplants in people with blood cancers like leukemia and lymphoma. Twelve patients will receive the transplant along with chemotherapy or radiation. The main goal is to see if the new ma…

This phase 1 trial is testing whether combining two drugs, azacitidine and abatacept, can shrink tumors in adults with T-cell lymphoma that has relapsed or not responded to prior treatment. Up to 20 participants will receive the drugs in 28-day cycles for up to 13 cycles. The stu…

This phase II trial is testing the drug trametinib in 50 people with advanced cancers that have a specific genetic change called an NF1 mutation. Trametinib blocks certain proteins that help cancer cells grow. The goal is to see if the drug can shrink tumors or stop them from get…

This study tests whether adding daratumumab to standard treatment (bortezomib and dexamethasone) can improve kidney function better than the usual approach (cyclophosphamide, bortezomib, and dexamethasone) in people newly diagnosed with multiple myeloma who also have kidney failu…

This phase II trial tests a combination of three targeted drugs—acalabrutinib, umbralisib, and ublituximab—in people with previously untreated mantle cell lymphoma. The drugs work by blocking signals that help cancer cells grow and by helping the immune system attack them. The st…

This study looks at how well the drug tafasitamab works in adults with diffuse large B-cell lymphoma (DLBCL) that has come back or not responded to previous treatment. Researchers will collect real-world data from 50 patients who are not eligible for a stem cell transplant. The m…

This phase 2 trial tests whether adding the drug daratumumab to a standard chemotherapy combination (bortezomib, cyclophosphamide, and dexamethasone) works better than the current standard (bortezomib, thalidomide, and dexamethasone) for newly diagnosed multiple myeloma patients …

This study tests whether the targeted drug inotuzumab ozogamicin can eliminate minimal residual disease (MRD) in adults with B-cell acute lymphoblastic leukemia (ALL) before they receive a stem cell transplant. Participants have either Philadelphia chromosome-positive or -negativ…

This phase 3 trial tests whether adding the targeted antibody isatuximab to a standard three-drug regimen (carfilzomib, lenalidomide, dexamethasone) can achieve deeper remissions in people newly diagnosed with multiple myeloma who are eligible for a stem cell transplant. Particip…

This phase 2 trial is testing the drug iberdomide (CC220) as a long-term maintenance therapy for people with newly diagnosed multiple myeloma who have already had a stem cell transplant. The goal is to see if taking iberdomide continuously can improve the depth of response and he…

This study looks at whether people with plasma cell disorders can safely recover from an autologous stem cell transplant at home instead of in the hospital. Researchers want to see if home recovery is practical, reduces infections, and keeps patients satisfied. About 91 adults ag…

This early-phase trial tests a new cell therapy called ANCHOR for people with B-cell lymphoma or leukemia that has returned or not responded to treatment. The therapy uses immune cells from a healthy donor that are engineered to recognize and attack cancer cells carrying the CD19…

This phase 2 trial is testing the drug abemaciclib in people whose primary brain tumors have come back after initial treatment. The goal is to see if the drug can shrink tumors or slow their growth. Participants take abemaciclib pills twice daily, and some take it before surgery …

This early-phase trial tests a new approach to treating certain blood cancers (like lymphoma and leukemia) that have come back or not responded to standard treatment. The therapy uses a patient's own immune cells, engineered to recognize and attack cancer cells (SYNCAR-001), alon…

This phase 1 trial tests a new approach for people with high-risk multiple myeloma who are already responding to their first or second line of therapy. The study uses a patient's own immune cells, engineered to recognize and attack the cancer (CART-BCMA), sometimes combined with …

This early-phase trial is testing a new therapy called CD19 t-haNK, which uses specially engineered natural killer cells to target and destroy cancer cells. It is being tested alone and with the drug rituximab in 10 adults with B-cell non-Hodgkin lymphoma that has come back or no…

This phase II trial is testing whether adding a targeted drug called inotuzumab ozogamicin to standard chemotherapy can help older adults with B-cell acute lymphoblastic leukemia or lymphoma. The study compares the combination to standard chemo alone in 68 participants. The goal …

This phase 3 trial tests whether adding the investigational drug epcoritamab to standard therapy (rituximab and lenalidomide) helps adults with follicular lymphoma that has returned or not responded to previous treatment. Participants receive either the standard therapy alone or …

This phase 2 trial is testing a combination of two drugs, rituximab and zanubrutinib, in people with hairy cell leukemia or its variant. The goal is to see if this treatment can shrink or eliminate the cancer. Participants take zanubrutinib pills daily and receive rituximab infus…

This early-stage study tests a new drug called IOA-244 in about 210 adults with advanced or metastatic cancers like lung cancer, melanoma, and lymphoma. The main goal is to see if the drug is safe and tolerable, both alone and combined with other treatments. Researchers also chec…

This study is testing two immunotherapy drugs, durvalumab and tremelimumab, in children and teens up to age 17 with advanced solid tumors or blood cancers that have not responded to standard treatments. The first part finds the safest dose, and the second part checks if the drugs…

This phase 2 trial tests whether the drug lenalidomide, taken as maintenance therapy, can delay the return of multiple myeloma in patients who have already responded to initial treatment. Participants take lenalidomide daily and are monitored for how long they remain free of dise…

This phase I trial tests the safety of adding ruxolitinib to a standard combination of dasatinib and dexamethasone for adults aged 40 and older with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The study starts with a low dose of ruxoli…

This study tests a drug called blinatumomab given after a stem cell transplant to help prevent relapse in people with B-cell acute lymphoblastic leukemia or B-cell non-Hodgkin lymphoma. About 44 participants will receive the drug as maintenance therapy. The goal is to see if it i…

This phase 2 trial investigates whether combining rituximab (an antibody therapy) with venetoclax (a targeted pill) can effectively treat marginal zone lymphoma in people who have not yet received any treatment for their cancer. The study enrolls adults with measurable disease an…

This phase 1 trial tests a new approach for people with multiple myeloma that has come back or stopped responding to at least three prior treatments. The study uses two different CAR T cell therapies—one targeting a protein called GPRC5D and another targeting BCMA—given together …

This phase 2 trial tests whether a combination of four drugs—daratumumab, bortezomib, lenalidomide, and dexamethasone—can stop high-risk smoldering multiple myeloma from progressing to active multiple myeloma. Participants must be 18 or older and meet specific high-risk criteria.…

This phase 3 trial tests a new drug, belantamab mafodotin, against a standard treatment (pomalidomide plus dexamethasone) in 325 people with multiple myeloma that has returned or stopped responding to prior therapy. The main goal is to see if the new drug delays cancer progressio…

This study tests a new treatment for a rare and aggressive blood cancer called primary plasma cell leukemia. The approach combines chemotherapy, a stem cell transplant, and two infusions of specially engineered immune cells (CAR-T cells) that target the cancer. The goal is to see…

This study tests a combination of two drugs, ixazomib and rituximab, in people with slow-growing B-cell non-Hodgkin lymphoma. The goal is to see how well the drugs shrink or control the cancer. About 33 adults with different types of this lymphoma are taking part.

This study tests a drug called belantamab mafodotin in people with multiple myeloma that has come back or stopped responding to treatment, and who also have kidney problems—from mild impairment to end-stage disease requiring dialysis. The drug is an antibody-drug conjugate that t…

This early-phase trial tests a new immune cell therapy called CS1-CAR T cells for people with multiple myeloma that has come back or not responded to treatment. The therapy involves taking a patient's own immune cells, engineering them in a lab to recognize and attack myeloma cel…

This trial investigates a new type of immunotherapy called CAR T-cell therapy that targets two proteins, CD19 and CD22, found on B-cell leukemia cells. The therapy is given along with chemotherapy to children and young adults whose leukemia has come back or has not responded to s…

This early-phase study tests the safety of combining two drugs, moxetumomab pasudotox and rituximab, for people with hairy cell leukemia that has not responded to standard treatment. About 18 adults will receive up to 8 cycles of the drugs through an IV. The main goal is to find …

This trial was designed to test a milder conditioning regimen using a radioactive antibody (90Y-Epratuzumab) followed by chemotherapy and a stem cell transplant for adults with CD22-positive B-cell acute lymphoblastic leukemia. The goal was to find the safest dose that still cont…

This phase II trial tests whether combining three drugs—bendamustine, obinutuzumab, and venetoclax—can improve outcomes for people with untreated mantle cell lymphoma. Bendamustine and venetoclax are chemotherapy drugs that kill or stop cancer cells from growing, while obinutuzum…

This study tests a new procedure called BEAM (Bariatric Endoscopic Antral Myotomy) to help people with obesity lose weight. The procedure uses a tube down the throat to make small cuts in the stomach muscle, aiming to change how the stomach empties. Twenty adults with a BMI betwe…

This early-phase trial is testing a new drug called venetoclax combined with standard chemotherapy drugs for people with aggressive B-cell lymphoma that has come back or stopped responding to treatment. The main goal is to find the highest safe dose of the new combination. About …

This early-phase study tests a new drug called BGB-11417 (sonrotoclax) in people with B-cell blood cancers that have come back or not responded to treatment. The goal is to find the safest dose and see how well it works alone or combined with other drugs. About 437 adults will ta…

This phase 2 trial is testing a combination of two drugs, acalabrutinib and rituximab, in elderly or frail patients who have not yet been treated for mantle cell lymphoma. The goal is to see how well the drugs shrink or control the cancer. The study involves 48 participants aged …

This phase 2 trial tests whether empagliflozin, a diabetes drug also known as Jardiance, can help people with glycogen storage disease type Ib (GSD-1b). GSD-1b causes low neutrophil counts, leading to frequent infections and bowel inflammation. The study gives empagliflozin orall…

This study was designed to test a new drug called linvoseltamab combined with standard chemotherapy drugs (bortezomib and lenalidomide) in people newly diagnosed with multiple myeloma who are eligible for a stem cell transplant. The goal was to see if this combination, with or wi…

This trial explores whether adding the drug tazemetostat (Tazverik) to standard CAR T cell therapy can help the immune cells better recognize and destroy lymphoma cells. It enrolls people with diffuse large B-cell lymphoma, follicular lymphoma, or mantle cell lymphoma who have al…

This phase 2 trial is testing a combination of four drugs (carfilzomib, lenalidomide, dexamethasone, and daratumumab) given before and after a stem cell transplant for people with multiple myeloma that has come back after prior treatment. The study includes 41 participants and ai…

This phase 1/2 trial tests the drug acalabrutinib (Calquence) in 49 people with central nervous system lymphoma that has come back or not responded to treatment. Participants take the tablet by mouth twice daily. The study aims to find the safest dose and see if the drug can shri…

This study tests a combination of three oral drugs—ixazomib, iberdomide, and dexamethasone—in patients over 70 with multiple myeloma that has returned after initial treatment. The goal is to see how many patients achieve a very good partial response or better. 75 participants wil…

This study is testing a combination of three drugs—obinutuzumab, ibrutinib, and venetoclax—for people with chronic lymphocytic leukemia (CLL) that has come back, not responded to treatment, or is newly diagnosed. The goal is to find the best dose and see how well the combination …

This early-phase trial tests the safety of giving patients modified immune cells from a donor to fight B-cell leukemia or lymphoma that has come back after a stem cell or organ transplant. The cells are designed to target a protein called CD19 on cancer cells. Only 19 patients ar…

This study tests a drug called iberdomide as maintenance therapy for people with multiple myeloma who have had a stem cell transplant. The goal is to see if more patients can stay on treatment for at least a year without the disease getting worse. About 40 adults will take iberdo…

This phase 3 trial tests whether a new combination of drugs—belantamab mafodotin, pomalidomide, and dexamethasone—works better than a standard combo for people with multiple myeloma that has returned or not responded to treatment. The study involves 21 Japanese adults who have al…

This phase 3 study tests whether adding the targeted drug belantamab mafodotin to standard medications (pomalidomide and dexamethasone) works better than another standard combo for people with multiple myeloma that has come back or stopped responding to treatment. About 302 parti…

This study tests a drug called acalabrutinib in 10 people with central nervous system (CNS) lymphoma that has returned or not responded to treatment. The goal is to see if the drug is safe and can shrink tumors. Acalabrutinib is already approved for another type of lymphoma and w…

This phase II trial tests whether adding the targeted drug acalabrutinib to standard R-CHOP chemotherapy improves outcomes for people with untreated mantle cell lymphoma. About 105 participants will receive the combination, then some will proceed to stem cell transplant. The stud…

This study tested a two-step drug combination for people newly diagnosed with mantle cell lymphoma, a type of blood cancer that is not curable with standard treatments. Twenty-three patients who were eligible for a stem cell transplant received rituximab and bendamustine followed…

This study tests a new drug called orelabrutinib in people with B-cell malignancies, such as certain lymphomas and leukemias. The drug works by blocking a protein that helps cancer cells grow. The trial has two parts: first finding the safest dose, then seeing how well it shrinks…

This early-phase trial tests the safety of giving patients their own genetically modified T-cells to fight relapsed B-cell acute lymphoblastic leukemia. The study includes children and young adults up to age 26 whose leukemia has returned or is hard to treat. The modified T-cells…

This early-phase trial tests a new treatment for people with Hodgkin or non-Hodgkin lymphoma who have had a stem cell transplant. The treatment uses the patient's own T cells, which are modified in a lab to recognize and attack cancer cells that carry a protein called CD30. The m…

This early-phase trial tests whether a child's own immune cells, genetically modified to recognize and attack leukemia cells, are safe and can be given in the right dose. Six children and young adults with CD19-positive acute lymphoblastic leukemia that has returned after treatme…

This phase II trial is testing new therapies, including the drug teclistamab, for people with multiple myeloma that has relapsed or not responded to treatment. About 300 participants will be enrolled in an adaptive platform design that allows adding new treatment arms over time. …

This phase 2 trial is testing a combination of three drugs—tafasitamab, lenalidomide, and rituximab—in people aged 80 and older with untreated diffuse large B-cell lymphoma (DLBCL). The goal is to see if this gentler, chemotherapy-free regimen can shrink or eliminate tumors after…

This phase 2 trial is testing a drug called elranatamab in 50 people with multiple myeloma that has relapsed or stopped responding after at least one prior treatment. Participants have already tried three main drug classes. The goal is to see if elranatamab can reduce the cancer …

This study tests whether people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) can safely stop taking acalabrutinib and obinutuzumab once their cancer responds very well, instead of continuing treatment indefinitely. The goal is to reduce serious side…

This early-phase study tests a new treatment for patients with relapsed or hard-to-treat lymphoma in the brain or spinal cord. The therapy uses the patient's own immune cells, modified to recognize and attack cancer cells. The main goals are to check safety and see if the treatme…

This early-phase trial tests a new treatment for people with a rare and hard-to-treat type of lymphoma that has spread to the brain or spinal cord. The therapy uses the patient's own immune cells, modified to target two markers (CD19 and CD22) on cancer cells, and is given throug…

This study tests a treatment using a patient's own immune cells, modified to find and attack cancer cells that carry a marker called CD19. It is for people with B-cell acute lymphoblastic leukemia that has not responded to standard treatments or has come back. The goal is to see …

This pilot study tests whether giving special immune cells called T-APCs after CAR T cell therapy can help the CAR T cells persist longer in the body and prevent leukemia from returning. It involves 30 children and young adults with relapsed or refractory CD19+ leukemia who have …

This early-stage study tests a new drug called HRS-3738 in people with two types of blood cancer—non-Hodgkin's lymphoma and multiple myeloma—that have returned or not improved after prior treatments. The main goals are to find a safe dose and check how well the drug works. About …

This phase 2 trial tests four different drug combinations in 373 patients aged 60 and older with untreated mantle cell lymphoma. The goal is to see which combination best delays cancer progression. Patients receive rituximab plus bendamustine, with or without bortezomib, followed…

This phase 3 trial tests whether adding the targeted drug acalabrutinib to standard chemotherapy (bendamustine and rituximab) helps people with untreated mantle cell lymphoma live longer without their cancer getting worse. About 635 patients aged 65 and older are taking part. The…

This phase 2 trial tests a new approach for people newly diagnosed with multiple myeloma who have a high-risk genetic change (P53 abnormality). The treatment combines standard chemotherapy with a double dose of specially engineered immune cells (CAR-T cells) and a stem cell trans…

This study tests a stem cell transplant from a matched unrelated donor for people with advanced blood cancers or blood disorders. Patients get chemotherapy and radiation before the transplant to prepare their body, then take drugs to prevent the donor cells from attacking their o…

This early-phase study tests whether adding mosunetuzumab after a stem cell transplant is safe for people with aggressive B cell lymphoma that has come back or not responded to prior treatments. Mosunetuzumab is an engineered antibody that helps the body's T cells recognize and k…

This study aimed to test a new CAR-T cell therapy that targets a protein called Igβ on cancer cells in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. The trial planned to enroll patients who had already tried at least two other treatments. However, the study …

This study tests a new treatment for people with a type of blood cancer called diffuse large B-cell lymphoma that has come back or not responded to prior therapy. The treatment combines two drugs (tafasitamab and lenalidomide) with standard chemotherapy, followed by a stem cell t…

This phase 2 trial tests a new treatment plan for teenagers and adults with B-cell acute lymphoblastic leukemia. Patients receive immunotherapy before a stem cell transplant using their own cells, followed by a CD22/CD19 CAR-T 'sandwich' to reduce the risk of relapse. The study a…

This early-stage study tested a combination of three immunotherapy drugs (blinatumomab, nivolumab, and ipilimumab) in 28 adults with a severe form of B-cell leukemia that had returned or not responded to prior treatments. The main goal was to find safe doses and identify side eff…

This pilot study tests a fludarabine-based drug regimen to prepare children with bone marrow failure syndromes for a bone marrow transplant from a matched sibling donor. The goal is to help the donor cells successfully take root while reducing serious side effects. The study incl…

This study tests two oral drugs, pirtobrutinib and venetoclax, in 46 people with Waldenström macroglobulinemia who have already had at least one prior treatment. The goal is to see if the combination can shrink the cancer and improve response rates. Researchers are also tracking …

This study tests a new treatment plan for adults with B-cell acute lymphoblastic leukemia (B-ALL) who cannot or choose not to have a donor stem cell transplant. The approach uses a 'sandwich' strategy: first, patients receive two types of CAR T-cells (targeting CD22 and CD19), th…

This early-phase trial is testing whether adding the drug venetoclax to a chemotherapy regimen originally designed for children can be safe and effective for adults aged 18-54 with a specific, aggressive form of B-cell acute lymphoblastic leukemia (Ph-like ALL). The study will en…

This study tests an experimental drug called GR1803 in 116 people with multiple myeloma that has come back or stopped responding to treatment. The goal is to see how well the drug shrinks or controls the cancer, and to check its safety. Participants receive the drug for up to 2 y…

This early-stage study tested a combination of two drugs (pembrolizumab and pralatrexate) in 13 people with peripheral T-cell lymphoma that had returned or not responded to prior treatment. The goal was to find the safest dose and see if the combo could shrink tumors. The approac…

This study tests whether the antiviral drug entecavir can prevent hepatitis B from reactivating in people with a type of blood cancer (CD20-positive B-cell lymphoma) who have had hepatitis B in the past but cleared it. The 84 participants will take entecavir before starting their…

This phase II trial tests a combination of eight chemotherapy drugs given in lower doses and shorter cycles to people with high-risk multiple myeloma. The goal is to prevent myeloma cells from regrowing between treatments, leading to longer remissions and better survival. The stu…

This phase 3 trial tests whether a less intense version of a standard chemotherapy regimen can reduce side effects by half while still controlling low-risk multiple myeloma in adults 65 and under. Participants receive a combination of drugs, a stem cell transplant, and three year…

This phase 2 trial tests whether adding venetoclax to ibrutinib and an anti-CD20 antibody can better clear minimal residual disease in people with newly diagnosed mantle cell lymphoma. About 210 patients will receive either the two-drug or three-drug combo for up to two years, pl…

This phase II trial tests a combination of three drugs—acalabrutinib, lenalidomide, and rituximab—in 60 people with untreated follicular lymphoma that has spread. The goal is to see if this chemo-free mix can make the cancer disappear completely. Participants take the drugs by mo…

This study tests a drug called loncastuximab tesirine in 21 people with Waldenström macroglobulinemia, a rare blood cancer, whose disease has not responded to at least two prior treatments. The goal is to see if the drug can shrink tumors and lower abnormal protein levels. Partic…

This phase 2 trial tests a new COVID-19 booster vaccine (GEO-CM04S1) in 80 people with chronic lymphocytic leukemia (CLL). The goal is to see if this vaccine triggers a stronger immune response than standard mRNA boosters. Participants will receive either the new vaccine or a sta…

This study tests whether the drug iberdomide can safely improve outcomes for people with multiple myeloma who had a less-than-ideal response after a stem cell transplant and previous maintenance therapy. Sixteen participants will take iberdomide and be monitored for disease progr…

This early-phase trial tests a gene therapy approach for people with HIV who also have lymphoma that has returned or not responded to treatment. Researchers take the patient's own stem cells, add anti-HIV genes in the lab, and return them after a stem cell transplant. The goal is…

This study tests a new drug called pirtobrutinib against other approved drugs for mantle cell lymphoma, a type of blood cancer. About 500 people who have already had at least one prior treatment will take part. The goal is to see if the new drug works better at controlling the di…

This phase 2 trial is testing the immunotherapy drug nivolumab in 55 patients with type B3 thymoma or thymic carcinoma that has worsened after platinum-based chemotherapy. The main goal is to see if nivolumab can stop the cancer from growing for at least 6 months. Researchers wil…

This phase 2 trial is testing a combination of four drugs—isatuximab, carfilzomib, lenalidomide, and dexamethasone—in 246 people newly diagnosed with high-risk multiple myeloma. The goal is to see if this intensive regimen can make the cancer undetectable (MRD-negative) and keep …

This trial aimed to test a new drug called CM313, a CD38-targeting antibody, combined with a chemotherapy regimen inspired by pediatric treatments for adults newly diagnosed with T-cell acute lymphoblastic leukemia (T-ALL). The goal was to see if the combination could improve rem…

This study tests a combination of three drugs (obinutuzumab, zanubrutinib, and lenalidomide) followed by a short course of chemotherapy (cytarabine) in 39 adults newly diagnosed with mantle cell lymphoma, a rare blood cancer. The goal is to see if this approach can shrink or elim…

This study tests whether adding the immunotherapy drug pembrolizumab to standard R-ICE chemotherapy can help people with diffuse large B-cell lymphoma that has returned or not responded to earlier treatment. About 65 adults will take part. The main goal is to see how many are ali…

This phase 2 trial tests a combination of four drugs (carfilzomib, daratumumab, lenalidomide, and dexamethasone) in 17 people with high-risk multiple myeloma. The goal is to see if the treatment can clear even tiny amounts of cancer left after initial therapy, known as minimal re…

This study gives venetoclax to people with certain blood cancers who already benefited from it in earlier studies. The main goal is to track side effects and safety over a longer period. About 165 participants will continue taking the drug to see how well it works and how safe it…

This study tests a new combination of three drugs—belantamab mafodotin, carfilzomib, and dexamethasone—in people whose multiple myeloma has returned and is no longer responding to lenalidomide. The trial has two parts: first, finding the safest dose, then testing that dose in up …

This phase 2 trial tests a new way of giving chemotherapy to people with high-risk multiple myeloma who have already had some treatment. Instead of high doses with long breaks, researchers give lower doses in shorter cycles to prevent cancer cells from regrowing. The goal is to i…

This phase 2 pilot study tests two new drug combinations—teclistamab plus daratumumab and talquetamab plus daratumumab—in 30 people newly diagnosed with high-risk multiple myeloma. The goal is to see if these treatments can make the cancer undetectable (MRD-negative complete remi…

This Phase 2 trial tests whether adding carfilzomib to ibrutinib improves outcomes for people with Waldenström's macroglobulinemia, a rare blood cancer. About 99 participants will receive either the combination or ibrutinib alone. The goal is to see if the combo leads to higher r…

This study tests a combination of two targeted drugs, ibrutinib and venetoclax, in 45 adults with a rare blood cancer called Waldenström macroglobulinemia who have a specific gene mutation (MYD88). The goal is to see if the combo can shrink the cancer significantly. Participants …

This study aimed to find safe doses of two experimental drugs (lisaftoclax and pelcitoclax) combined with standard FLAG chemotherapy for adults with T-cell acute lymphoblastic leukemia that returned or didn't respond to treatment. The trial was withdrawn before enrolling any part…

This study was designed to test whether adding an experimental drug and special immune cells to standard care could help critically ill adults with severe pneumonia, especially those with sepsis or lung failure. The trial was withdrawn before enrolling any participants, so no res…

This study was designed to see if adding two immune treatments (NAI and iNKT cells) to standard care could help critically ill adults with severe pneumonia, sepsis, or lung failure recover. It planned to enroll ICU patients and follow them for 90 days. However, the study was with…

This phase 2 trial is testing two drug combinations—iberdomide plus dexamethasone, with or without daratumumab—in 140 newly diagnosed multiple myeloma patients aged 65 or older who are not eligible for a stem cell transplant. The goal is to see how well these treatments control t…

This study tests a new treatment for adults with a specific type of leukemia (Philadelphia chromosome-positive B-ALL). The treatment uses a patient's own immune cells that are modified in a lab to find and attack cancer cells. The goal is to see if this approach is safe and can h…

This phase 2 trial tests the drug acalabrutinib in people with chronic lymphocytic leukemia (CLL) who also have a blood condition called autoimmune hemolytic anemia (AIHA) that has come back or not responded to treatment. The study aims to see if acalabrutinib can control the ane…

This study is for people with systemic amyloidosis, a disease where abnormal proteins build up in organs. It tests the long-term safety of an experimental drug called AT-02. About 120 adults will receive the drug and be monitored for side effects and how the drug behaves in the b…

This study tests a new chemotherapy-free treatment for marginal zone lymphoma, a slow-growing blood cancer. It combines two drugs, Copanlisib and Rituximab, to see if they can control the disease better than Rituximab alone, while avoiding harsh chemo side effects. The trial incl…

This study tests whether adding isatuximab to a standard three-drug regimen (bortezomib, lenalidomide, and dexamethasone) can help people with newly diagnosed multiple myeloma who cannot have a stem cell transplant live longer without their cancer worsening. About 475 participant…

This phase 2 trial tests obinutuzumab, a targeted antibody, in 56 people with newly diagnosed marginal zone lymphoma who need treatment but cannot have or have failed local therapy. The goal is to see if this drug can shrink tumors without the side effects of chemotherapy. Partic…

This study tests a new treatment for people with high-risk B-cell non-Hodgkin lymphoma that has come back. After a stem cell transplant, patients receive genetically modified immune cells designed to recognize and attack cancer cells. The goal is to see if this approach is safe a…

This study tests a device that delivers specific light and sound patterns to the brain, aiming to slow the progression of mild-to-moderate Alzheimer's disease. About 670 participants will use the device at home for an hour daily over a year, with half receiving a sham (inactive) …

This study aimed to test a new CAR-T cell therapy that targets three proteins (CD20, CD19, and CD22) on cancer cells in people with B-cell lymphoma that returned or didn't respond to treatment. The therapy was designed to help the immune system attack the cancer. However, the tri…

This study tests a combination of two drugs, belantamab mafodotin and nirogacestat, in people with multiple myeloma that has returned or not responded to at least three prior treatments. The goal is to find a safe dose and see how well the combination shrinks tumors. About 106 ad…

This early-phase trial is testing whether adding the drug venetoclax to a standard treatment regimen can help adults with a specific type of leukemia (Philadelphia chromosome-positive ALL). The study involves 20 participants and aims to find the safest dose of venetoclax when com…

This study is testing a new drug called Golcadomide (BMS-986369) in about 85 people in Japan whose T-cell lymphoma has come back or not responded to treatment. The goal is to check the drug's safety and how well it works against the cancer. Participants will receive the drug and …

This study tests a new way to do stem cell transplants for children and young adults (up to age 22) with blood cancers like leukemia. Doctors remove certain immune cells from donated stem cells to lower the risk of graft-versus-host disease, a serious complication. The goal is to…

This study tests whether giving the immunotherapy drug pembrolizumab before standard surgery can shrink tumors in people with a specific type of uterine cancer (MMRd). Twelve participants will receive 9 cycles of pembrolizumab before their hysterectomy. The goal is to see how man…

This early-stage trial is testing an experimental oral drug called APG-2575 in people with relapsed or refractory chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL). The main goal is to check the drug's safety and find the best dose. About 74 participants will take…

This study tests a new way to give a drug called isatuximab as a quick shot under the skin, instead of a long IV drip, for people newly diagnosed with multiple myeloma who cannot have a stem cell transplant. The shot is combined with three standard chemotherapy drugs. The goal is…

This phase 2 trial tests whether adding the targeted drug acalabrutinib to standard chemotherapy (R-CHOP) improves outcomes for people with untreated diffuse large B-cell lymphoma (DLBCL). About 450 participants will receive one cycle of R-CHOP, then two-thirds will get five more…

This study tests whether adding the targeted drug rituximab to standard chemotherapy can improve outcomes for children and teens with aggressive B-cell lymphoma or leukemia. About 650 participants from Europe will receive different treatment schedules to find the best balance of …

This early-stage study tests an oral drug called MK-1026 in 12 Chinese adults with blood cancers (like lymphoma or leukemia) that returned or didn't respond to prior therapies. The main goals are to check the drug's safety and how the body processes it. Researchers will also look…

This phase 2 trial is testing whether leflunomide, a drug used for arthritis, can delay the onset of multiple myeloma in 27 people with high-risk smoldering multiple myeloma. The study includes both African-American and European-American participants to see if the drug works diff…

This phase 3 trial compares three treatment approaches for people with previously untreated chronic lymphocytic leukemia (CLL): continuous ibrutinib alone, a fixed-duration combination of venetoclax plus obinutuzumab, or a fixed-duration combination of ibrutinib plus venetoclax. …

This early-stage study tests a new approach for adults with B-cell acute lymphoblastic leukemia (B-ALL) that has returned or not responded to standard treatment. Researchers take a patient's own T cells, modify them in the lab to recognize and attack leukemia cells, and infuse th…

This phase II study tests a daily pill called PCI-32765 (ibrutinib) in 86 people with chronic lymphocytic leukemia or small lymphocytic lymphoma who are over 65 or have a specific genetic change (17p deletion). These groups often do not respond well to standard chemotherapy. Part…

This early-phase study tests an experimental drug called DS-3201b in about 100 adults with non-Hodgkin lymphoma whose cancer has come back or is not responding to current treatments. The main goals are to find a safe dose and see how the drug works in the body. The study also che…

This study planned to test a type of immunotherapy called BCMA CAR-T cells in people with high-risk multiple myeloma who still had signs of cancer after a stem cell transplant. The goal was to see if the treatment could clear remaining cancer cells and improve outcomes. However, …

This phase 2 trial tests a combination of three drugs—acalabrutinib, lenalidomide, and either rituximab or obinutuzumab—in people with untreated mantle cell lymphoma. The goal is to see how well the combo clears cancer cells from the blood and shrinks tumors. Participants receive…

This phase 2 trial tests a combination of two drugs, tislelizumab and pemetrexed, in 28 adults with a rare type of brain lymphoma (primary DLBCL of the CNS) that has relapsed or not responded to standard treatment. The goal is to see if the combination can shrink tumors and impro…

This early-phase trial tests a personalized cell therapy for adults aged 60 and older with B-cell acute lymphoblastic leukemia (ALL) who are in first remission. Researchers take a patient's own immune cells, modify them in the lab to recognize and attack leukemia cells, and infus…

This phase 3 study compares a new oral drug called pirtobrutinib (LOXO-305) against two standard treatment combinations (idelalisib plus rituximab or bendamustine plus rituximab) in 238 adults with chronic lymphocytic leukemia or small lymphocytic lymphoma who have already been t…

This phase 2 trial tests a combination of two drugs—TTI-622 and pembrolizumab (Keytruda)—in about 10 adults with diffuse large B-cell lymphoma that has come back or not responded to treatment. TTI-622 blocks a protein called CD47 that cancer cells use to hide from the immune syst…

This study tests a new treatment for adults with a type of leukemia (T-ALL) that has come back or not responded to standard therapy. The treatment combines an immunotherapy drug (PD-1 inhibitor) with a targeted drug (venetoclax) and chemotherapy. The goal is to see if this combin…

This study tests a new combination of drugs (belantamab mafodotin, bortezomib, and dexamethasone) against a standard combo (daratumumab, bortezomib, and dexamethasone) in 494 people whose multiple myeloma has come back or stopped responding to treatment. The goal is to see if the…

This study tests whether a new combination of drugs—belantamab mafodotin plus bortezomib and dexamethasone—works better than a standard combination (daratumumab plus bortezomib and dexamethasone) for people in Japan with multiple myeloma that has come back or stopped responding t…

This early-phase trial tests a new type of CAR T-cell therapy for adults with B-cell lymphoma that has come back or not responded to treatment. The therapy uses a patient's own immune cells, modified to better target and kill cancer cells. The study aims to find the safest dose a…

This Phase 3 trial tests whether a new drug combination (belantamab mafodotin plus bortezomib and dexamethasone) works better than a standard combination (daratumumab plus bortezomib and dexamethasone) for people with multiple myeloma that has come back or stopped responding to t…

This phase 2 trial tests a new type of CAR-T cell therapy that targets two proteins (CD19 and CD22) on lymphoma cells, aiming to prevent the cancer from escaping treatment. It involves 100 adults with relapsed or refractory large B-cell lymphoma who have not responded to standard…

This study tests a combination of four drugs (daratumumab, bortezomib, cyclophosphamide, and dexamethasone) in 41 people with multiple myeloma that has spread outside the bones, known as extramedullary disease. The goal is to see how well the treatment works and how safe it is. P…

This study tests a combination of two drugs, copanlisib and venetoclax, in adults with mantle cell lymphoma that has returned or stopped responding to treatment. The goal is to find the safest dose and see how well the drugs shrink tumors. Eight participants are enrolled in this …

This study tests a three-step treatment for elderly patients (ages 60-80) with a high-risk type of lymphoma called double-expressor DLBCL. First, patients receive a chemotherapy-free drug combination. Depending on how well the cancer responds, they then get standard chemotherapy …

This early-stage trial is testing an experimental therapy called NKX019 for people with certain blood cancers (like lymphoma and leukemia) that have come back or not responded to standard treatments. NKX019 uses donor immune cells (natural killer cells) that are engineered to fin…

This early-phase trial tests whether adding glucarpidase (Voraxaze) to standard methotrexate and rituximab can safely lower methotrexate levels in the blood for people with central nervous system lymphoma. About 58 participants will receive different doses of methotrexate along w…

This pilot phase 2 study tests a combination of ibrutinib (taken daily) and a short course of fludarabine (given in cycles 3 and 4) in 29 patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. The goal is to see how many patients achieve a …

This study tests a stem cell transplant method for people with blood cancers like leukemia or lymphoma. The approach uses chemotherapy, total body radiation, and a drug called cyclophosphamide after the transplant to prevent graft-versus-host disease, where donor cells attack the…

This early-phase trial tests a two-part treatment for people with relapsed or chemotherapy-resistant B-cell leukemia or lymphoma. First, patients receive a chemotherapy drug (cyclophosphamide) to help prepare the body. Then, they get an infusion of their own T cells that have bee…

This study tests a new device called the Edwards EVOQUE eos mitral valve replacement system. It is for people with a leaky mitral valve who are too high-risk for open-heart surgery. The study will check if the device is safe and works well by looking at complications, heart funct…

This study was designed to test a combination of two drugs—golcadomide and nivolumab—in people with non-Hodgkin lymphoma whose cancer did not respond or came back after CAR-T cell therapy. The goal was to find a safe dose and see if the combo could shrink tumors. However, the tri…

This Phase 2 trial tests the drug ibrutinib in 154 people with relapsed or refractory chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or B-cell prolymphocytic leukemia (B-PLL). Participants take ibrutinib pills daily for 28-day cycles. The main goal is to se…

This study tests whether a combination of three drugs (obinutuzumab, ibrutinib, and venetoclax) can shrink tumors in people with untreated follicular lymphoma. The trial includes 40 adults with stage II to IV disease. The goal is to see if the combination works better than any si…

This early-phase study tests a combination of four drugs (cyclophosphamide, pomalidomide, dexamethasone, and daratumumab) in people with multiple myeloma that has returned or stopped responding to prior treatments. The goal is to find the safest dose and see if the combination ca…

This study is tracking 200 adults with multiple myeloma whose cancer has returned or stopped responding to treatment. They are receiving teclistamab, a drug that helps the immune system find and destroy myeloma cells. Researchers are measuring how many patients respond to the dru…

This study tests several drug combinations and stem cell transplants in 1,400 children with Langerhans cell histiocytosis, a rare immune disease. The goal is to prevent the disease from coming back and reduce lasting problems like hormone deficiencies and brain issues. Researcher…

This phase 2 trial tests a chemotherapy-light combination of three drugs—rituximab, polatuzumab vedotin, and glofitamab—in 125 patients over 60 with aggressive B-cell lymphoma who cannot tolerate full-dose standard chemo. The goal is to see if this gentler approach can control th…

This study tests whether adding lenalidomide (Revlimid) to the standard high-dose melphalan before an autologous stem cell transplant can improve outcomes for people with relapsed multiple myeloma. In the first phase, researchers find the safest dose of lenalidomide to combine wi…

This study tests three different drug combinations containing selinexor (Xpovio) for people whose multiple myeloma has returned or stopped responding to treatment. About 18 adults will receive a combination chosen by their doctor. The goal is to see how well these treatments shri…

This early-phase study tests the safety of specially engineered immune cells (armored CAR T cells) in people with certain blood cancers that have not responded to standard treatments. The cells are made from the patient's own blood and designed to better target and attack cancer …

This phase 2 trial tests a combination of two drugs, acalabrutinib and tafasitamab, in 26 patients with marginal zone lymphoma that has come back or not responded to previous treatment. The goal is to see how well the combo shrinks or controls the cancer and to check for side eff…

This early-stage trial tests a new gene therapy (PM359) for people with a rare immune disorder called chronic granulomatous disease (CGD). The treatment takes a patient's own blood stem cells, fixes a specific genetic error using a precise editing tool called prime editing, and r…

This study tests a combination of three drugs (orelabrutinib, zuberitamab, and chemotherapy) in 65 adults with untreated marginal zone lymphoma, a slow-growing blood cancer. The goal is to see if the treatment can make all signs of cancer disappear for at least 24 months. Partici…

This Phase 3 trial is testing whether a new combination of drugs—iberdomide, daratumumab, and dexamethasone—can better control multiple myeloma that has come back or stopped responding to treatment, compared to a standard three-drug regimen. About 939 participants who have had 1 …

This study looks at whether people with multiple myeloma who have no signs of cancer after a stem cell transplant and at least one year of maintenance therapy can safely stop taking their medication. Researchers will use advanced imaging and lab tests to detect even tiny amounts …

This phase II trial is testing a combination of two drugs—tazemetostat pills and mosunetuzumab injections—in 23 people with follicular lymphoma who have not yet received treatment. The goal is to see if the combination is safe and leads to a complete response (disappearance of ca…

This study tests a new drug called 9-ING-41, given alone or with chemotherapy, in adults with cancers that have not responded to standard treatments. The goal is to see if the drug is safe and can help control the disease. About 350 people with various advanced cancers, including…

This early-phase trial tests a new approach for patients with aggressive B-cell lymphoma that has come back after treatment. Researchers take a patient's own immune cells (T cells), modify them in the lab to better recognize and kill lymphoma cells, and give them back after a sta…

This phase 2 trial is testing an experimental cell therapy called TAK-007 in 27 adults with B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. Participants first receive chemotherapy to lower certain white blood cells, then get one or three injections o…

This phase 2 trial is testing the drug daratumumab in 42 people with high-risk MGUS or low-risk smoldering multiple myeloma—early, pre-cancerous conditions that can lead to multiple myeloma. The goal is to see if daratumumab can produce a deep response (very good partial response…

This phase 2 trial is testing a combination of two drugs—ibrutinib and rituximab—in 50 people with untreated, slow-growing mantle cell lymphoma. The goal is to see if this drug pair can shrink or eliminate the cancer and keep it from progressing. Researchers will also study the t…

This phase 2 trial is testing a personalized cell therapy called axi-cel for people with aggressive B-cell lymphoma that has come back or not responded to treatment, and who cannot undergo a stem cell transplant. The therapy uses the patient's own immune cells, which are modified…

This study tests a combination of four drugs (isatuximab, pomalidomide, elotuzumab, and dexamethasone) in people with multiple myeloma that has come back or stopped responding to at least two prior treatments. The goal is to see how well the drug combo controls the cancer. The st…

This study tests a drug called CPI-613 in people with relapsed or hard-to-treat Burkitt lymphoma or high-grade B-cell lymphoma. About 24 participants aged 12 and older who have not responded to at least one prior treatment will receive the drug. The goal is to see if the drug can…

This early-phase study tests a combination of three drugs (ibrutinib, lenalidomide, and rituximab) in people with mantle cell lymphoma that has returned or not responded to prior treatment. The main goal is to find the safest dose of this combination by monitoring side effects. U…

This Phase 2 trial tests whether adding daratumumab to a three-drug regimen (carfilzomib, lenalidomide, dexamethasone) works better than the three drugs alone for people newly diagnosed with multiple myeloma. About 310 participants will be randomly assigned to one of the treatmen…

This early-phase study tests a personalized cancer vaccine designed to target each patient's unique tumor mutations. It is given along with pembrolizumab after standard rituximab treatment for follicular lymphoma. The goal is to see if this approach is feasible and can boost the …

This study tests a combination of two drugs, duvelisib and venetoclax, in 55 people with relapsed or refractory chronic lymphocytic leukemia (CLL) or Richter's syndrome. Duvelisib blocks a protein that helps cancer cells survive, while venetoclax targets another survival protein.…

This study tests a new treatment for cancers linked to the Epstein-Barr virus (EBV), such as Hodgkin lymphoma and nasopharyngeal carcinoma. The treatment uses immune cells from healthy donors that are specially trained to attack EBV-infected cells. These cells are stored in a ban…

This study tests a new drug called Iberdomide (CC-220) alone or with other cancer drugs in people with multiple myeloma, a type of blood cancer. The trial has two parts: first, finding the safest dose, and second, seeing how well it shrinks tumors. About 466 participants are invo…

This phase 2 trial tests a personalized approach for young adults (18-65) with high-risk chronic lymphocytic leukemia (CLL) who haven't been treated before. Patients first get a combination of venetoclax and obinutuzumab, then their treatment is adjusted based on whether cancer c…

This study tests whether adding four doses of rituximab to an intensified chemotherapy regimen improves outcomes for children and teens with advanced B-cell non-Hodgkin lymphoma or B-cell acute leukemia. About 200 participants in China will receive the new treatment, and research…

This study tests whether a stem cell transplant from a healthy donor can safely treat people with severe T-cell problems. Participants receive chemotherapy and antibody therapy before the transplant, followed by donor stem cells. The goal is to see if the new immune system can co…

This study was designed to compare a CAR T-cell therapy called Liso-cel against standard treatments for adults with follicular lymphoma that had come back or stopped responding to previous therapy. The trial was a large Phase 3 study planned at multiple hospitals worldwide, but i…

This phase 2 trial tests a combination of the immunotherapy drug glofitamab plus two chemotherapy drugs (gemcitabine and oxaliplatin) in 40 adults with refractory diffuse large B-cell lymphoma that did not respond to initial treatment. The main goal is to see how many patients ac…

This phase 2 trial tests whether using teclistamab or talquetamab (immune cell redirectors) after initial treatment can improve outcomes for newly diagnosed multiple myeloma. 103 patients receive either teclistamab with lenalidomide or teclistamab with talquetamab, depending on t…

This Phase III trial tests whether a de-escalated (less intense) version of the standard MATRix chemotherapy regimen works as well for newly diagnosed primary CNS lymphoma. About 331 patients will receive either the standard four courses of MATRix or a reduced schedule with one c…

This study tests a stem cell transplant using donors who are not a perfect match for patients with blood cancers like leukemia and lymphoma. Doctors give special drugs after the transplant to help prevent the donor cells from attacking the patient's body. The goal is to see if th…

This study was designed to test a new treatment called Anti-CD7 CAR-T for people with T-cell acute lymphoblastic leukemia or lymphoma that had come back or not responded to standard therapy. The treatment uses a patient's own immune cells, modified to target and kill cancer cells…

This study tests an experimental drug called iopofosine I 131 in people with certain blood cancers (like Waldenstrom macroglobulinemia, multiple myeloma, and lymphomas) that have come back or not responded to standard treatments. The drug delivers radiation directly to cancer cel…

This study tests whether giving patients with high-risk multiple myeloma specially engineered T-cells (CAR T-cells) after a stem cell transplant can safely improve outcomes. The T-cells are designed to target two proteins on myeloma cells, CD19 and BCMA. Researchers are monitorin…

This phase 3 trial compares the experimental drug nemtabrutinib (a daily pill) against standard chemotherapy combinations for people with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who lack a specific genetic change (TP53 mutation)…

This early-phase study tests a combination of two drugs, acalabrutinib and durvalumab, in people with primary central nervous system (CNS) lymphoma—a rare and aggressive brain cancer. The study includes up to 25 patients whose cancer has returned after prior treatment or who cann…

This phase 3 trial tests whether the targeted drug zanubrutinib works better than the standard chemo combination of bendamustine plus rituximab for people with untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). About 590 participants who cannot tole…

This phase 2 trial tests daratumumab (Darzalex) combined with other drugs as a first treatment for multiple myeloma patients who are not eligible for a stem cell transplant. The goal is to see if this combination can achieve very good partial remission or better after 8 cycles, a…

This phase 2 trial tests whether adding daratumumab, an antibody that targets a protein on leukemia cells, to standard chemotherapy can clear all signs of cancer in adults with very high-risk T-cell acute lymphoblastic leukemia (T-ALL). About 31 patients aged 18-65 will receive t…

This study follows about 100 people with multiple myeloma who previously received an experimental cell therapy called P-BCMA-101. Researchers will monitor them for up to 15 years to see how safe and effective the treatment remains over time. A safety switch drug called rimiducid …

This study tests whether adding two more drugs (carfilzomib and dexamethasone) to the standard maintenance drug lenalidomide after a stem-cell transplant can keep multiple myeloma from coming back longer. About 180 adults who have already had a transplant and are in stable condit…

This early-phase trial tests a new treatment for multiple myeloma, a type of blood cancer. It uses a patient's own immune cells, modified to target a protein called BCMA on cancer cells, and may be combined with a drug called lenalidomide. The main goal is to find the safest dose…

This Phase 2 trial tests whether adding the targeted drug ponatinib to standard chemotherapy can improve outcomes for adults with a specific, high-risk type of acute lymphoblastic leukemia called BCR/ABL1-like ALL. The study enrolls 32 patients aged 18-65 who have not yet been tr…

This phase 2 trial tests an oral drug called sonrotoclax (BGB-11417) in 100 adults with chronic lymphocytic leukemia or small lymphocytic lymphoma that has come back or stopped responding to prior treatments. The goal is to see if the drug can shrink or control the cancer. It is …

This phase 3 trial tests whether adding a CAR T-cell therapy (ide-cel) to standard lenalidomide maintenance can improve outcomes for adults with newly diagnosed multiple myeloma who had a poor response to stem cell transplant. About 79 participants will receive either the combina…

This study tests a new type of CAR T cell therapy, called ALLO-501A, made from donor cells (not the patient's own). It is for adults with large B-cell lymphoma or chronic lymphocytic leukemia/small lymphocytic lymphoma that has come back or not responded to other treatments. The …

This phase 2 trial is testing a combination of four drugs—selinexor, bortezomib, dexamethasone, and daratumumab—in 62 patients with multiple myeloma that has returned or not responded to prior treatments. The goal is to see how many patients achieve a significant reduction in can…

This study tests a two-step treatment for people with early-stage MALT lymphoma, a slow-growing cancer of the lymph nodes. First, patients take a targeted drug called orelabrutinib. Then, based on how well the tumor responds, they receive an ultra-low dose of radiation (4Gy) to a…

This phase 2 study is testing a combination of three drugs—acalabrutinib, umbralisib, and ublituximab—in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma. The goal is to see if this triple therapy can improve complete remission rates. The study enrolle…

This study tests a combination of three drugs (bortezomib, lenalidomide, and dexamethasone) in people newly diagnosed with multiple myeloma, a type of blood cancer. The goal is to find the safest dose and see how well the drugs work together to control the disease. The trial incl…

This phase 2 trial tests a personalized approach for chronic lymphocytic leukemia (CLL). Patients first receive two oral drugs (zanubrutinib and venetoclax). Only those who still have detectable cancer cells after treatment get an additional infusion drug (obinutuzumab). The goal…

This study tests a new way for cancer doctors and primary care doctors to work together to help cancer survivors manage other health problems like high blood pressure, diabetes, and high cholesterol. About 800 adults with certain cancers and at least one of these conditions will …

This phase II trial is testing two drugs, obinutuzumab and ibrutinib, as the first treatment for people with indolent non-Hodgkin's lymphoma, a slow-growing blood cancer. The goal is to see how many patients respond to the combination. The study involves 30 participants and is no…

This study tests an experimental drug called valemetostat tosylate in people with B-cell lymphoma whose cancer has returned or not responded to prior treatments. About 141 participants will receive the drug to see if it can shrink tumors. The goal is to find a new option for hard…

This study tests a stem cell transplant using a milder chemotherapy-like regimen to treat children and young adults (up to age 28) with various immune system disorders. The goal is to help the donor stem cells settle in the body with fewer side effects. The study involves 20 part…

This study tests a new drug combination for people with a type of slow-growing blood cancer called follicular lymphoma that has a high tumor burden. The treatment adds tazemetostat (a targeted pill) to a standard chemo-immunotherapy regimen, but uses a shorter course of chemother…

This early-phase trial tests two drugs—venetoclax and tocilizumab—in people with a specific type of multiple myeloma (t(11;14)) that has come back or stopped responding to treatment. The study includes both African American and non-African American participants to see how safe th…

This study tests an experimental oral drug, CC-99282, in people with non-Hodgkin lymphoma that has come back or stopped responding to treatment. The drug is given alone or with other lymphoma medicines. The main goals are to check safety and find the best dose, while also seeing …

This early-phase study tests experimental cell therapies in 40 adults with relapsed and refractory multiple myeloma who have tried at least three prior treatments. The main goal is to check safety and find the right dose. While not a cure, it aims to control the disease and may l…

This early-phase study tests a new type of immunotherapy called BAFFR-CAR T cells for adults with B-cell acute lymphoblastic leukemia that has come back or not responded to at least two prior treatments. The therapy involves reprogramming a patient's own immune cells to recognize…

This study tests a new targeted drug, IPI-145, added to standard chemotherapy and immunotherapy (FCR) for younger adults (18-65) with untreated chronic lymphocytic leukemia (CLL). The goal is to see if the combination is safe and can achieve deep remissions where no cancer cells …

This early-stage trial tests a new therapy called SENTI-202, which uses specially designed immune cells (CAR NK cells) to find and attack cancer cells in people with certain blood cancers like acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The cells are 'off-the…

This study tests a drug called leniolisib in 12 people aged 12 to 75 with certain primary immunodeficiency disorders. The goal is to see if the drug is safe and can help control immune system problems. Participants will receive three different doses of the drug, and researchers w…

This phase 2 study tests a combination of three drugs—acalabrutinib, venetoclax, and obinutuzumab—as an initial treatment for chronic lymphocytic leukemia (CLL). The goal is to see if this combo can make the cancer undetectable in the bone marrow after 15 cycles of therapy. The s…

This study tests a combination of two drugs, vemurafenib (a pill) and obinutuzumab (an infusion), in 30 people with previously untreated hairy cell leukemia. The goal is to see how many patients achieve a complete response, meaning no signs of cancer after treatment. Participants…

This phase 3 trial tests whether adding daratumumab to a standard three-drug regimen (VRd) improves outcomes for people with newly diagnosed multiple myeloma who can undergo high-dose therapy. About 709 participants will receive either the four-drug combo or the standard three dr…

This phase 3 trial is testing whether adding the drug isatuximab to a standard combination of lenalidomide and dexamethasone, with or without bortezomib, can improve outcomes for newly diagnosed multiple myeloma patients aged 65 to 79 who are not eligible for a stem cell transpla…

This phase 2 study tests the drug selinexor combined with one of three other cancer drugs (carfilzomib, daratumumab, or pomalidomide) in 96 adults with multiple myeloma whose disease has worsened despite current treatment. Participants continue on the combination until the cancer…

This study tests an experimental drug called WTX-330 in 100 adults with advanced solid tumors or non-Hodgkin lymphoma that have not responded to standard treatments. The trial has two parts: first, finding the safest dose and schedule, then expanding to see how well the drug work…

This phase 2 trial is testing whether adding venetoclax to ibrutinib can eliminate resistance mutations in people with chronic lymphocytic leukemia (CLL) who have developed resistance to ibrutinib alone. The study enrolls 28 participants who are already taking ibrutinib and have …

This early-phase study tests a new treatment for people with certain B-cell blood cancers (lymphoma, ALL, or CLL) that have returned or not responded to standard therapy. The treatment uses the patient's own T cells, which are modified in the lab to recognize and attack cancer ce…

This phase 2 trial is testing whether adding the immunotherapy drug nivolumab to a standard chemotherapy regimen (DA-REPOCH) can improve outcomes for people with aggressive B-cell non-Hodgkin lymphoma. The study enrolls 30 patients with various subtypes of the disease. The main g…

This study tests a new treatment plan for people newly diagnosed with multiple myeloma, a type of blood cancer. The plan combines several drugs, including bortezomib and melphalan, with stem cell transplants and long-term maintenance therapy. The goal is to see if this approach w…

This study tests a new drug called TNB-383B in about 220 adults with multiple myeloma that has come back or not responded to at least three prior treatments. The drug works by helping the immune system attack cancer cells. The main goals are to find the safest dose and check for …

This study tracks how well the drug epcoritamab works for 150 adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who have already tried at least two other treatments. Researchers will measure tumor shrinkage and side effects in everyday medical practice, not…

This phase 3 trial tests whether adding the drug isatuximab to standard treatment helps people with newly diagnosed multiple myeloma achieve deeper remission and live longer without the cancer progressing. About 662 participants will receive either standard therapy or standard th…

This phase II trial tests whether adding the targeted drug acalabrutinib to standard chemotherapy (bendamustine and rituximab) improves outcomes for people with untreated Waldenstrom's macroglobulinemia, a rare blood cancer. About 63 participants will receive the three-drug combo…

This phase 2 trial was designed to test a combination of rituximab, venetoclax, and bortezomib in patients with diffuse large B-cell lymphoma that had come back or stopped responding to treatment. The goal was to see how many patients would have their tumors shrink or disappear. …

This study tests a modified plan to prevent and treat cytomegalovirus (CMV) infection in people with blood cancers who have had a donor stem cell transplant. CMV is a common virus that can cause serious problems after transplant. The study involves 153 participants and looks at w…

This phase 2 study tests whether adding the drug acalabrutinib to the CAR T-cell therapy lisocabtagene maraleucel (liso-cel) can improve outcomes for people with aggressive B-cell lymphomas that have come back or not responded to treatment. About 28 adults will receive acalabruti…

This trial tests whether a blood-based test called KidneyIntelX can help doctors better manage type 2 diabetes patients with early to moderate chronic kidney disease. The test estimates the risk of rapid kidney function decline over five years. Researchers will see if using this …

This trial is testing a new imaging tracer called FLT, which is used with a PET scan to measure how fast tumors are growing. The study includes people with various cancers or those awaiting a biopsy for a suspicious mass. The goal is to see if FLT PET imaging can help find and di…

This trial evaluates a new device called PointCheck that aims to detect severe neutropenia—a dangerous drop in infection-fighting white blood cells—without needing a blood sample. The study includes about 210 people with diffuse large B-cell lymphoma or multiple myeloma who are r…

This study offers voluntary screening for newborns in North Carolina to detect a wide range of rare health conditions early. Using a small blood sample already collected at birth, the program tests for dozens of disorders, including spinal muscular atrophy, cystic fibrosis, and m…

This study is testing a blood screening program to find multiple myeloma and its early stages (MGUS and smoldering myeloma) in Black adults aged 50 and older. Participants get a simple blood test and fill out questionnaires about their experience and knowledge of the disease. Tho…

This study tests whether a single urine sample (spot urine) can detect myeloma proteins as accurately as the standard 24-hour urine collection. Researchers will compare results from 180 multiple myeloma patients starting a new treatment. If the spot test works well, it could make…

This study tests a new app called RACS that helps primary care doctors screen older adults for early cognitive decline. The app includes risk questions, a symbol matching task, and voice tasks. Researchers will enroll 500 adults aged 60 and older to see if the tool is easy to use…

This study tests a telemedicine program called FOCUS that helps advanced cancer patients manage common symptoms like trouble sleeping, worry, tiredness, and low mood. The program uses counseling techniques delivered through a phone app. Researchers will enroll 120 adults with adv…

This study tests an 8-week online stress management program for health students in Sfax, Tunisia. The program combines cognitive-behavioral therapy and mindfulness meditation through videos, exercises, and motivational messages. Researchers will measure changes in stress, anxiety…

This study tests whether a specific massage technique called Peng's Fenjin Tuina can reduce pain from superior cluneal nerve entrapment syndrome, a condition that causes pain in the lower back and buttocks. Researchers will compare it to standard massage in 70 adults aged 18 to 7…

This study looks at whether playing pickleball for 12 weeks can improve thinking skills like attention and memory, as well as motor skills like balance and strength, in adolescents aged 14-18 with mild intellectual disability. Thirty-two students will either play pickleball three…

This study tests a text-message counseling program designed to help young adults ages 18 to 25 reduce or stop their cannabis use. Participants must use cannabis at least three days a week and live in Tennessee or Colorado. The program uses peer support and counseling delivered vi…

This study looks at whether fasting for 24 hours before and after chemotherapy is safe and doable for people with Hodgkin or Diffuse Large B Cell Lymphoma. 40 participants will either fast or follow standard care, tracking side effects, diet, and quality of life. The goal is to s…

This study looks at whether moderate-to-vigorous aerobic exercise, called Braining, can help people with bipolar depression recover faster and prevent future depressive episodes. Fifty-four participants will be split into three groups: one doing supervised aerobic exercise three …

This study follows nearly 90,000 farmers, their spouses, and pest control workers in Iowa and North Carolina over many years. Researchers track their exposure to pesticides and other farm chemicals, then monitor who develops cancer or other diseases. The goal is to identify which…

This study screens up to 10,000 people with blood disorders or healthy volunteers to see if they can safely join other active research studies at the National Heart, Lung, and Blood Institute. Participants undergo clinical, imaging, and lab tests. If no suitable study is availabl…

This study collects white blood cells from 120 people aged 3 to 65 with leukemia or lymphoma that hasn't been cured by standard treatments. The cells are gathered through a procedure called leukapheresis, then processed and frozen for future use in CAR T-cell therapy. The goal is…

This study collects small skin samples from people with primary immunodeficiency or immune regulation disorders, as well as from healthy volunteers. Researchers will use these cells to create cell lines for laboratory research. The goal is to better understand immune diseases and…

This study looks at how well the heart, lungs, and muscles work together in people who have had a stem cell transplant. Researchers want to find out why transplant survivors have a higher risk of heart disease. About 350 adults with blood cancers will be followed for two years af…

This study is investigating how common muscle loss, known as sarcopenia, is in people with blood cancers like leukemia, lymphoma, and myeloma. Researchers will measure body composition using DXA scans and track hospital stays, disease progression, and survival. The goal is to see…

This study looks at whether a new genomic test called the Molecular Functional (MF) Portrait can quickly provide useful information for treating lymphoma. Researchers will use tumor tissue already collected from 111 adults with diffuse large B-cell lymphoma to see if test results…

This study follows 800 adults who have had their first ischemic stroke in Central Norway for up to 10 years. Researchers will track how physical activity, medication use, and control of blood pressure and cholesterol affect the risk of death, another stroke, or severe disability.…

This long-term study looks at people and families with a higher chance of developing blood or lymph node cancers like leukemia or lymphoma. Researchers collect medical histories, genetic samples, and sometimes perform exams to find inherited genes or environmental triggers. The g…

This study is looking at whether a blood test that measures cell-free DNA (cfDNA) can help doctors know how well first-line treatment is working in people with follicular lymphoma. Researchers will collect blood samples before, during, and after standard treatment, and compare cf…

This pilot study is testing a nanochip (ILN biochip) to see if it can monitor how well treatment is working and detect relapse in people with diffuse large B-cell lymphoma. About 73 patients will provide blood samples for the chip to analyze genetic markers. The goal is to find o…

This study looks at how often cancer patients experience cachexia (unintentional weight loss and appetite loss) and how this affects both patients and their primary caregivers emotionally. About 192 patients and their caregivers will fill out questionnaires during supportive care…

This study looks at the genetic makeup of rare blood diseases like Castleman disease and Langerhans cell histiocytosis. Researchers will analyze blood or tissue samples from 135 participants to find genetic changes that could be targeted by existing or experimental therapies. The…

This study looks at whether a special type of testing, called leukemia profiling, can help find personalized treatment options for children and young adults up to age 30 with recurrent, refractory, or high-risk leukemias. Researchers analyze the genetic changes in each patient's …

This phase II trial, called MATCH, is testing whether treating cancer based on the genetic makeup of a patient's tumor works better than standard treatments. Over 6,400 adults with advanced solid tumors, lymphomas, or multiple myeloma that have not responded to prior therapy are …

This study does not provide any new treatment. It follows about 1,000 adults who previously received CAR T-cell gene therapy at the NIH. Researchers will check for long-term side effects through blood tests, clinic visits, and annual phone calls for up to 15 years, as required by…

This study explores whether the types of bacteria living in a person's gut can influence how well CAR-T cell therapy works for diffuse large B-cell lymphoma. Researchers will track changes in the gut microbiome of 69 patients from before treatment up to 18 months afterward. The g…

This study will observe 30 adults in Taiwan with relapsed or refractory multiple myeloma who are taking elranatamab as part of their regular care. Researchers will track how quickly the cancer responds, how long the response lasts, and overall survival. The goal is to understand …

This study looks at the cost-effectiveness of three treatments for chronic lymphocytic leukemia (CLL) in patients aged 65 and older. Researchers compared ibrutinib alone or with rituximab against bendamustine plus rituximab, measuring both healthcare costs and quality of life. Th…

This study looks back at medical records of 500 adults with aggressive B-cell lymphoma that has a MYC gene change. Researchers want to see if a stronger chemotherapy plan called CARMEN leads to better survival and remission rates compared to other treatments. Since it's a review …

This study tracks 56 follicular lymphoma patients to see how long their COVID-19 and other vaccine immunity lasts while they receive chemotherapy and maintenance therapy. Researchers will collect blood samples at several time points to measure immune responses. The goal is to und…

This study tests whether a wearable patch called TempTraq can detect fevers earlier than standard temperature checks in cancer patients receiving immunotherapy. The goal is to see if continuous monitoring reduces the risk of severe cytokine release syndrome (CRS), a serious side …

This pilot study aimed to see if it is possible to use neuropsychological tests to measure thinking, memory, and emotional health in adults who received CAR-T therapy for aggressive lymphoma at least six months earlier. The study was withdrawn before enrolling any participants, s…

This observational study follows 321 Italian patients with relapsed or refractory chronic lymphocytic leukemia (CLL) who are treated with venetoclax-based regimens outside of clinical trials. The goal is to describe their clinical features and outcomes, such as how long they live…

This study looks at how frailty—a state of weakness and reduced physical function—affects the risk of severe side effects from chemotherapy in people aged 70 and older with cancer. Researchers will assess 160 patients using various tests for frailty, muscle loss, and overall heal…

This study looks at why people with HIV and certain cancers caused by KSHV (Kaposi sarcoma herpesvirus) may lose bone density faster. Researchers will review past CT scans and health records from 40 adults treated at the NIH between 2005 and 2020. The goal is to find factors link…

This study observes 357 people with multiple myeloma to see how long it takes for the disease to come back after their first treatment. Participants visit their clinic every 3 months and receive standard care. The goal is to better understand relapse timing in real-life practice,…

This study explores whether smartphone sensors can detect early changes in behavior that might signal cognitive decline. About 100 adults aged 65 and older living in assisted living facilities will have an app on their phones that tracks movement, typing patterns, and app usage f…

This early-phase trial is testing whether ketoconazole, a drug normally used for fungal infections, can get into brain tumors (gliomas) in enough amounts to possibly slow their growth. About 80 adults with different grades of glioma will take low doses of the drug before their sc…

This study is not testing a new drug or treatment. Instead, it will observe how doctors in Russia currently treat chronic lymphocytic leukemia (CLL) in everyday practice. About 6000 adults with CLL will be followed for up to 2 years to collect information on their health, treatme…

This research study collects tissue, blood, and other samples from 2,400 people diagnosed with breast, colon, kidney, liver, multiple myeloma, or prostate cancer at a young age. The goal is to identify genetic changes that may explain why these cancers occur early, especially in …

This study looks at how histiocytosis—a group of rare disorders—may affect memory, thinking, and brain structure. Researchers will test 13 adults with these conditions using thinking tasks and MRI scans. The goal is to better understand brain changes, not to provide treatment.…

This study looks at whether a self-administered geriatric assessment can help predict serious side effects in people aged 60 and older with Non-Hodgkin lymphoma who are starting chemotherapy. The goal is to see if this assessment can identify who is at higher risk for hospitaliza…

This study looks at whether the size and shape of the thymus gland, along with the radiation dose it receives, can predict a drop in immune cells (lymphocytes) during chest radiation for stage III lung cancer. Researchers will collect data from standard scans and blood tests of 4…

This study tests whether adding automatic reminders to echocardiogram (heart ultrasound) reports can increase the number of patients with heart valve disease who see a cardiologist within six months. Researchers will randomly assign 300 patients' reports to receive no prompt, a p…

This study looks at skin and blood samples from 200 people with ichthyosis (a genetic condition causing dry, scaly skin) and healthy volunteers. Researchers want to find specific markers that could help them understand the disease better and develop new treatments. No treatment i…

This study looks at whether a test called MMprofiler can help doctors decide on the best treatment for people with multiple myeloma, a type of blood cancer. About 250 patients who are candidates for systemic treatment will have their tumor tested, and doctors will fill out questi…

This study looks at whether mepolizumab, a drug already used to reduce asthma attacks, can also improve physical activity and exercise tolerance in people with severe asthma. Researchers will track daily steps and activity levels in 62 adults over six months. The goal is to see i…

This study tracks 40 people with nasal polyps and severe asthma who are taking mepolizumab, a drug that reduces inflammation. Researchers collect nose, blood, and sputum samples before treatment and at 3, 6, and 12 months to see how the drug affects symptoms, nose bacteria, and g…

This study follows children born moderately or late preterm (32-36 weeks) to age 9, measuring their thinking, movement, language, behavior, and growth. Researchers compare these kids to full-term peers to understand long-term effects. The goal is to learn how early development pr…

This study follows 50 people who have already received an experimental CAR T cell therapy for certain blood cancers like lymphoma. No new treatment is given; instead, researchers will check for long-term side effects and how well the therapy works over 15 years. The goal is to be…

This pilot study looks at whether light, self-paced swimming is a tolerable activity for people with ME/CFS and related conditions like Long COVID and fibromyalgia. Participants will swim for 15-30 minutes at their own pace and track symptoms and heart rate variability using an a…

This study was designed to track pregnancies in women with rare autoimmune and systemic diseases to understand complications and improve care. It planned to enroll women with conditions like lupus, rheumatoid arthritis, and scleroderma. However, the study was withdrawn before any…

This study watches 50 people with chronic lymphocytic leukemia (CLL) who are starting a type of drug called a BTK inhibitor. These drugs can cause high blood pressure and irregular heartbeats. Participants will use a wearable device at home to track their heart rhythm and blood p…

This study looks at whether tracking tiny bits of tumor DNA in the blood (ctDNA) can help predict how B-cell non-Hodgkin lymphoma will progress. Researchers will collect blood samples from 60 patients before and during treatment. The goal is to see if changes in ctDNA levels matc…

This study follows 178 patients who previously received an AvenCell CAR-T cell therapy for cancers like lymphoma, leukemia, or prostate cancer. Researchers will track delayed side effects, including new cancers or autoimmune issues, for years. No new treatment is given—this is pu…

This study follows about 150 people who previously received Caribou cell therapy for blood cancers like lymphoma or leukemia. Researchers will check for long-term side effects and overall survival for up to 15 years after treatment. No new treatment is given—this is just observat…

This study collects information from 100 adults with breast, lung, gastrointestinal cancer, or multiple myeloma. Participants fill out weekly online surveys about their symptoms and treatment experiences for at least 12 weeks. The goal is to learn how symptoms change over time an…

This study uses artificial intelligence to analyze the shape of individual myeloma cells from bone marrow samples. The goal is to predict genetic abnormalities (called FISH abnormalities) without relying on subjective human review. If it works, this AI method could make genetic t…

This study creates a registry of 240 patients hospitalized with decompensated heart failure with preserved ejection fraction. Researchers will track medical history, body composition, imaging, and blood markers to see how these factors relate to short- and long-term outcomes. The…